# 2025年11月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 微器官芯片揭示肿瘤源性G-CSF通过VEGFA-KDR级联通路远程调控肺预转移微环境

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275332](https://pubmed.ncbi.nlm.nih.gov/41275332)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41275332
**DOI：** 10.1002/advs.202518584

### 第一部分 原文与翻译

**英文原标题：** Micro-Organ Chip Deciphers Tumor-Derived G-CSF as Remote Commander of Lung Pre-Metastatic Niche via VEGFA-KDR Cascade.

**英文摘要原文：**
Metastasis is the leading cause of cancer-related mortality. During metastatic progression, distant organs form a pre-metastatic niche (PMN), creating a permissive microenvironment that facilitates circulating tumor cell (CTC) colonization. To investigate pulmonary PMN formation in breast cancer, a micro-organ chip is employed that enables contact-independent coculture of tumor and lung tissues. This model reveals that PMN formation is governed by tumor-secreted factors without requiring direct tumor cell contact and exhibits non-tumor-type specificity. It is found that coculture with tumor tissue upregulates vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2/KDR) in lung capillary cells. Through integrated single-cell RNA sequencing and cytokine array analysis, granulocyte colony stimulating factor (G-CSF) is identified as a key tumor-derived mediator that modulates the pre-metastatic niche through activating the VEGFA-KDR signaling axis in the lung, thereby promoting angiogenesis and PMN development. This study highlights the G-CSF-KDR axis as a potential therapeutic target for inhibiting breast cancer metastasis.

**中文摘要译文：**
转移是癌症相关死亡的主要原因。在转移过程中，远处器官会形成预转移微环境（PMN），创造一个有利于循环肿瘤细胞（CTC）定植的微环境。为研究乳腺癌中肺部预转移微环境的形成，本研究采用了一种微器官芯片，该芯片能够实现肿瘤和肺组织的非接触式共培养。该模型揭示，预转移微环境的形成受肿瘤分泌因子的调控，无需肿瘤细胞直接接触，并且表现出非肿瘤类型特异性。研究发现，与肿瘤组织共培养会上调肺毛细血管细胞中血管内皮生长因子（VEGF）受体-2（VEGFR2/KDR）的表达。通过整合单细胞RNA测序和细胞因子芯片分析，粒细胞集落刺激因子（G-CSF）被确定为关键的肿瘤源性介质，它通过激活肺部的VEGFA-KDR信号轴来调节预转移微环境，从而促进血管生成和预转移微环境的形成。本研究强调了G-CSF-KDR轴作为抑制乳腺癌转移的一个潜在治疗靶点。

### 第二部分 AI 大师评价

本研究巧妙地利用微器官芯片技术，在体外模拟了原发肿瘤与远处器官间的非接触式相互作用，旨在揭示乳腺癌肺部预转移微环境的形成机制。研究通过单细胞测序等技术，精准识别出肿瘤分泌的G-CSF是关键的远程信号分子。其核心发现是，G-CSF通过激活肺部内皮细胞的VEGFA-KDR信号通路，促进血管生成，从而“培育”出适宜癌细胞定植的微环境。这项工作不仅揭示了转移前的重要分子事件，更提出了G-CSF-KDR轴这一极具潜力的新型抗转移治疗靶点，具有重要的临床转化价值。

---

## 2. PTPN9通过去磷酸化IGF1R减轻胆管癌中由IGF1R介导的对酪氨酸激酶抑制剂的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275311](https://pubmed.ncbi.nlm.nih.gov/41275311)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41275311
**DOI：** 10.1186/s13046-025-03594-2

### 第一部分 原文与翻译

**英文原标题：** PTPN9 dephosphorylates IGF1R and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma.

**英文摘要原文：**
Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options. Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib. Biomarker studies that can identify potential responders to mTKI therapy are crucial for improving treatment outcomes. In this study, we examined the expression of protein tyrosine phosphatase non-receptor type 9 (PTPN9) in CCA patients treated with surufatinib and analyzed its association with treatment response. Immunoprecipitation coupled with mass spectrometry (IP-MS) was performed to identify novel PTPN9 substrates. Orthotopic mouse models, biochemical assays, structural analyses, and functional experiments were conducted to validate these novel findings. Single-cell RNA sequencing, ELISA, and immunohistochemistry were utilized to investigate microenvironmental tumor-promoting factors.CCA patients with surufatinib non-response exhibited significantly decreased PTPN9 expression compared to that response to surufatinib. PTPN9 knockdown in orthotopic models led to reduced sensitivity to surufatinib. IGF1R was identified as a new substrate of PTPN9, which preferably to dephosphorylate IGF1R at Y1166. In clinical tissues, PTPN9 expression was inversely correlated with IGF1R Y1165/1166 phosphorylation. Establishment of a surufatinib-resistant CCA cell line further confirmed decreased PTPN9 expression and elevated IGF1R signaling. In vivo blockade of IGF1R signaling significantly enhanced surufatinib sensitivity. Mechanistically, crystal structure analysis revealed Tyr333 and Asp335 as key PTPN9 residues interacting with IGF1R; mutation of these residues restored IGF1R signaling and abolished the tumor-suppressive effect of PTPN9. Furthermore, cancer-associated fibroblasts (CAFs) were identified as the major source of IGF1 in CCA microenvironment, essential for IGF1R-driven tumor progression.In summary, the PTPN9-IGF1R axis plays a pivotal role in modulating mTKI sensitivity and tumor progression in CCA. This axis serves as a promising biomarker for identifying potential mTKI beneficiaries and represents a potential therapeutic target to enhance mTKI efficacy and overcome resistance.

**中文摘要译文：**
胆管癌（CCA）是一种侵袭性恶性肿瘤，治疗选择有限。越来越多的证据表明，一部分CCA患者可以从多酪氨酸激酶抑制剂（mTKI）（如索凡替尼）中获益。能够识别mTKI治疗潜在应答者的生物标志物研究对于改善治疗效果至关重要。在本研究中，我们检测了接受索凡替尼治疗的CCA患者中非受体型蛋白酪氨酸磷酸酶9（PTPN9）的表达，并分析了其与治疗反应的关联。我们采用免疫沉淀联合质谱（IP-MS）技术来鉴定PTPN9的新型底物。通过原位小鼠模型、生物化学测定、结构分析和功能性实验对这些新发现进行了验证。利用单细胞RNA测序、ELISA和免疫组织化学技术研究了微环境中的促肿瘤因子。与索凡替尼治疗有效者相比，治疗无效的CCA患者PTPN9表达显著降低。在原位模型中敲低PTPN9导致对索凡替尼的敏感性降低。IGF1R被鉴定为PTPN9的一个新底物，PTPN9优先在Y1166位点对IGF1R进行去磷酸化。在临床组织中，PTPN9的表达与IGF1R Y1165/1166位点的磷酸化水平呈负相关。索凡替尼耐药的CCA细胞系的建立进一步证实了PTPN9表达的降低和IGF1R信号通路的增强。在体内阻断IGF1R信号通路可显著增强对索凡替尼的敏感性。机制上，晶体结构分析揭示Tyr333和Asp335是PTPN9与IGF1R相互作用的关键残基；这些残基的突变恢复了IGF1R信号通路，并消除了PTPN9的肿瘤抑制效应。此外，癌症相关成纤维细胞（CAFs）被确定为CCA微环境中IGF1的主要来源，这对IGF1R驱动的肿瘤进展至关重要。总之，PTPN9-IGF1R轴在调节CCA中mTKI敏感性和肿瘤进展方面发挥着关键作用。该信号轴可作为一个有前景的生物标志物，用于识别潜在的mTKI受益者，并代表了一个潜在的治疗靶点，以增强mTKI疗效和克服耐药性。

### 第二部分 AI 大师评价

本研究旨在揭示蛋白酪氨酸磷酸酶PTPN9在胆管癌（CCA）对多靶点酪氨酸激酶抑制剂（mTKI）耐药中的作用及其分子机制。研究综合运用了临床样本分析、蛋白质谱、原位小鼠模型、结构生物学和单细胞测序等前沿技术，系统地验证了其科学假设。核心发现是，PTPN9通过在Y1166位点去磷酸化IGF1R来抑制其活性，PTPN9表达下调导致IGF1R信号通路激活，从而介导了对索凡替尼的耐药。此研究创新性地阐明了PTPN9-IGF1R轴作为调控CCA药物敏感性的关键通路，不仅为筛选mTKI治疗的优势人群提供了潜在的生物标志物，也为克服耐药性提供了新的联合治疗靶点，具有重要的临床转化价值。

---

## 3. ATG4B与SESN3的新型调控回路促进T细胞白血病的发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275290](https://pubmed.ncbi.nlm.nih.gov/41275290)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41275290
**DOI：** 10.1186/s13046-025-03588-0

### 第一部分 原文与翻译

**英文原标题：** A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis.

**英文摘要原文：**
BACKGROUND: T cell acute lymphoblastic leukemia is a fatal hematological malignancy. Despite the treatment progress, no targeted therapy is available currently, which urges to deepen the understanding of the underlying mechanism of T-ALL cell growth/survival. Autophagy is a conserved cellular process, which plays a dual role in human cancers. Nevertheless, many aspects of the involvement of autophagy in T-ALL are not fully understood.

METHODS: T-ALL patient cells and normal control cells were subjected to RT‒qPCR analysis. Gene silence and overexpression was used to study the function of ATG4B and sestrin 3 (SESN3) in T-ALL cells. Atg4b deficient mice were used to study the role of Atg4b in normal hematopoietic cells and T cell development. The efficacy of S130, an ATG4B inhibitor to suppress T-ALL cell growth was evaluated in xenograft models.

RESULTS: The results showed that the expression of several autophagy-related genes (especially ATG4B) was significantly higher in T-ALL patient cells than control cells. ATG4B ablation decreased autophagic flux and inhibited T-ALL cell growth. In contrast, Atg4b depletion had mild effects on normal hematopoiesis and T cell development. RNA-seq data and subsequent studies revealed a novel regulatory circuit of ATG4B and SESN3, and the results indicated that SESN3 hampered T-ALL cell growth via the inhibition of both mTOR/S6K/protein synthesis pathway and autophagy. Importantly, S130 exhibited anti-leukemia activity in xenograft models.

CONCLUSIONS: The present study demonstrates that a novel ATG4B-SESN3 regulatory circuit plays a crucial role in T cell leukemogenesis, which suggests that targeting ATG4B is a promising strategy for T-ALL treatment.

**中文摘要译文：**
背景：T细胞急性淋巴细胞白血病是一种致命的血液系统恶性肿瘤。尽管治疗已取得进展，但目前尚无靶向疗法，这迫切需要加深对T-ALL细胞生长/存活潜在机制的理解。自噬是一种保守的细胞过程，在人类癌症中扮演双重角色。然而，自噬参与T-ALL的许多方面尚未被完全阐明。

方法：对T-ALL患者细胞和正常对照细胞进行RT-qPCR分析。利用基因沉默和过表达研究ATG4B和sestrin 3 (SESN3)在T-ALL细胞中的功能。使用Atg4b缺陷小鼠研究Atg4b在正常造血细胞和T细胞发育中的作用。在异种移植模型中评估了ATG4B抑制剂S130抑制T-ALL细胞生长的功效。

结果：结果显示，几种自噬相关基因（特别是ATG4B）的表达在T-ALL患者细胞中显著高于对照细胞。ATG4B的缺失降低了自噬流并抑制了T-ALL细胞的生长。相比之下，Atg4b的耗竭对正常造血和T细胞发育影响轻微。RNA-seq数据及后续研究揭示了一个ATG4B和SESN3的新型调控回路，结果表明SESN3通过抑制mTOR/S6K/蛋白质合成途径和自噬来阻碍T-ALL细胞的生长。重要的是，S130在异种移植模型中表现出抗白血病活性。

结论：本研究表明，一个新型的ATG4B-SESN3调控回路在T细胞白血病发生中起着关键作用，这提示靶向ATG4B是治疗T-ALL的一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在探究自噬相关基因ATG4B在T细胞急性淋巴细胞白血病（T-ALL）中的作用机制。研究者通过结合患者样本分析、细胞及动物模型，揭示了ATG4B与SESN3之间存在一个全新的调控回路，该回路对T-ALL的发生至关重要。此项工作的创新之处在于发现了这一特异性调控网络，并证实靶向ATG4B（如使用抑制剂S130）能有效抑制白血病细胞生长，而对正常造血影响较小，为缺乏有效靶向药物的T-ALL治疗提供了极具潜力的新策略。

---

## 4. 用于检测CIN3+病变的三基因甲基化标志物组合在荷兰人群筛查项目阴道自取样本中的临床验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275248](https://pubmed.ncbi.nlm.nih.gov/41275248)
**期刊：** Clinical epigenetics
**PMID：** 41275248
**DOI：** 10.1186/s13148-025-02020-w

### 第一部分 原文与翻译

**英文原标题：** Clinical validation of a three-marker methylation panel to detect CIN3+ in vaginal self-samples in the Dutch population-based screening programme.

**英文摘要原文：**
BACKGROUND: The use of vaginal self-sampling for cervical cancer screening is promising and increasing. However, triage cytology cannot be performed on vaginal self-sampling material after a high-risk human papilloma virus (hrHPV)-positive result. In our recent discovery study, we identified a three-marker panel with high sensitivity (82%) and specificity (74%) for CIN3 or worse (CIN3+). In the present study, we performed the clinical validation of this three-marker panel using real-world hrHPV-positive vaginal self-samples obtained through the Dutch screening programme.

METHODS: The markers LHX8, EPB41L3 and ANKRD18CP were analysed using quantitative methylation-specific PCR (QMSP) on a consecutive cohort of hrHPV-positive vaginal self-samples (n = 2482: 408 CIN3+ and 2074 <CIN3). Diagnostic performance was assessed using sensitivity and specificity derived from receiver operating characteristics (ROC) analysis.

RESULTS: The three-marker panel showed 73% (298/408) sensitivity and 79% (1640/2071) specificity to detect CIN3+, and identified 96% (21/22) of cervical cancer cases. A scenario analysis was performed on a virtual population of 100 000 hrHPV-positive women using vaginal self-sampling, comparing our methylation triage test with current cytology triage testing. This analysis revealed that more cancers (864 vs. 684 or 770 for 80 or 90% uptake) would be detected with our methylation panel, while referral rates (29% vs. 31% for both 80 and 90% uptake) and detection of CIN3 (72% vs. 68 or 77% for 80 or 90% uptake) would be similar for methylation and cytology.

CONCLUSION: Compared to cytology triage testing, DNA methylation triage analysis using our three-marker panel offers an appropriate alternative to detect CIN3+ in hrHPV-positive vaginal self-samples. Implementation of the DNA methylation triage test would not only increase cancer detection, but would also eliminate the need for physician visits for cytological triage testing. In addition, it would accelerate referral decisions, ultimately reducing uncertainty and ensuring timely screening completion for all women.

**中文摘要译文：**
背景：阴道自取样用于宫颈癌筛查前景广阔且应用日益增多。然而，对于高危型人乳头瘤病毒（hrHPV）阳性的阴道自取样样本，无法进行分流细胞学检查。在我们近期的发现性研究中，我们鉴定出一个对CIN3或更严重病变（CIN3+）具有高灵敏度（82%）和特异性（74%）的三基因标志物组合。在本研究中，我们利用从荷兰筛查项目中获得的真实世界hrHPV阳性阴道自取样样本，对这一三基因标志物组合进行了临床验证。

方法：我们采用定量甲基化特异性PCR（QMSP）技术，对一个由hrHPV阳性阴道自取样样本组成的连续队列（n = 2482，其中408例为CIN3+，2074例为<CIN3）中的LHX8、EPB41L3和ANKRD18CP这三个标志物进行了分析。诊断性能通过受试者工作特征（ROC）分析得出的灵敏度和特异性进行评估。

结果：该三基因标志物组合在检测CIN3+病变方面显示出73%（298/408）的灵敏度和79%（1640/2071）的特异性，并识别出96%（21/22）的宫颈癌病例。我们对一个包含10万名使用阴道自取样的hrHPV阳性女性的虚拟人群进行了情景分析，将我们的甲基化分流检测与现行的细胞学分流检测进行了比较。分析显示，与细胞学检测相比，我们的甲基化标志物组合能检测出更多的癌症病例（在80%或90%的筛查参与率下，分别为864例 vs. 684例或770例），而转诊率（甲基化29% vs. 细胞学均为31%）和CIN3的检出率（甲基化72% vs. 细胞学68%或77%）则相似。

结论：与细胞学分流检测相比，使用我们的三基因标志物组合进行DNA甲基化分流分析，为检测hrHPV阳性阴道自取样样本中的CIN3+病变提供了一种合适的替代方案。实施DNA甲基化分流检测不仅能提高癌症检出率，还能免除女性为进行细胞学分流检查而需就医的环节。此外，它还能加快转诊决策，最终减少不确定性，确保所有女性都能及时完成筛查。

### 第二部分 AI 大师评价

本研究旨在荷兰大规模人群筛查项目中，对一个由三个DNA甲基化标志物组成的组合（LHX8, EPB41L3, ANKRD18CP）在hrHPV阳性阴道自取样样本中检测CIN3+病变的有效性进行临床验证。研究采用QMSP方法，在真实世界队列中证实了该标志物组合具有良好的诊断性能（73%灵敏度，79%特异性），且情景分析显示其癌症检出率优于传统细胞学分流。该研究的创新价值在于，为日益普及的阴道自取样筛查提供了一种精准、高效的分流工具，有望简化筛查流程、减少不必要的就医环节，从而提升筛查效率和患者体验。

---

## 5. 机器学习驱动的液体活检预测晚期胃癌患者对紫杉醇联合雷莫西尤单抗的治疗反应：来自前瞻性IVY试验的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275215](https://pubmed.ncbi.nlm.nih.gov/41275215)
**期刊：** Molecular cancer
**PMID：** 41275215
**DOI：** 10.1186/s12943-025-02526-0

### 第一部分 原文与翻译

**英文原标题：** A machine-learning powered liquid biopsy predicts response to paclitaxel plus ramucirumab in advanced gastric cancer: results from the prospective IVY trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在通过一种基于机器学习的液体活检技术，为接受紫杉醇联合雷莫西尤单抗治疗的晚期胃癌患者建立一个疗效预测模型。这项前瞻性IVY试验的结果表明，利用液体活检数据进行智能分析，有望筛选出最可能从该治疗方案中获益的患者群体。该方法的创新性在于其无创性和前瞻性验证，为胃癌的精准治疗提供了极具价值的新工具，但其具体的预测效能和模型的普适性有待摘要或全文发表后进一步评估。

---

## 6. 40种人类常见疾病的血浆代谢组遗传图谱：定位与疾病风险相关的因果代谢物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275212](https://pubmed.ncbi.nlm.nih.gov/41275212)
**期刊：** Genome medicine
**PMID：** 41275212
**DOI：** 10.1186/s13073-025-01578-7

### 第一部分 原文与翻译

**英文原标题：** Genetic atlas of plasma metabolome across 40 human common diseases: mapping causal metabolites to disease risk.

**英文摘要原文：**
BACKGROUND: Metabolites are closely linked to individual health and disease conditions. Identifying genetic factors influencing metabolite levels in specific diseases can enhance our understanding of disease etiology and informing precision medicine. This study aims to characterize the genetic architecture of metabolites in specific disease states and explore their potential biological functions.

METHODS: We conducted a comprehensive genome-wide metabolite quantitative trait locus (metQTL) analysis of 249 plasma metabolites across 40 disease states, based on nuclear magnetic resonance (NMR) data. To predict the biological significance of metQTLs, we performed a systematic functional annotation encompassing the analysis of genomic positions, heritability assessment, histone and transcription factor (TF) enrichment, effector gene identification, and potential drug targets evaluation. Furthermore, Mendelian randomization (MR) analyses were applied to uncover causal metabolites associated with diseases, and polygenic risk score (PRS) models were constructed to assess their predictive capacity for disease outcomes.

RESULTS: Across 40 common disease types, we identified 283,563 metQTL-metabolite association pairs involving 249 metabolites and 149,984 metQTLs derived from 26,536 independent loci. Functional annotations indicated that these metQTLs influence chromatin activity and transcription factor binding, suggesting their key roles in epigenetic regulation. Mendelian randomization analysis revealed 104 reliable causal evidence between metabolites and diseases. Additionally, metQTL-derived disease PRS models demonstrated excellent performance in the risk stratification of 8 diseases, offering a framework for translating genetic resources into clinical applications. An online platform, "metQTL-Atlas" (https://metqtl.whu.edu.cn/home), has been established for convenient browsing and downloading of our comprehensive results.

CONCLUSIONS: This study provides a comprehensive resource that delineates the genetic architecture of metabolites across diverse disease contexts, offering new insights into disease etiology and advancing precision medicine through enhanced risk prediction and therapeutic target discovery.

**中文摘要译文：**
背景：代谢物与个体健康和疾病状况密切相关。识别特定疾病中影响代谢物水平的遗传因素，有助于加深我们对疾病病因的理解并指导精准医疗。本研究旨在描绘特定疾病状态下代谢物的遗传结构，并探索其潜在的生物学功能。

方法：我们基于核磁共振（NMR）数据，对40种疾病状态下的249种血浆代谢物进行了全面的全基因组代谢物数量性状位点（metQTL）分析。为预测metQTL的生物学意义，我们进行了系统的功能注释，包括基因组位置分析、遗传度评估、组蛋白和转录因子（TF）富集分析、效应基因鉴定以及潜在药物靶点评估。此外，我们应用孟德尔随机化（MR）分析来揭示与疾病相关的因果代谢物，并构建了多基因风险评分（PRS）模型以评估其对疾病结局的预测能力。

结果：在40种常见疾病类型中，我们鉴定出283,563个metQTL-代谢物关联对，涉及249种代谢物和源自26,536个独立位点的149,984个metQTL。功能注释表明，这些metQTL影响染色质活性和转录因子结合，提示它们在表观遗传调控中发挥关键作用。孟德尔随机化分析揭示了代谢物与疾病之间104个可靠的因果关系证据。此外，基于metQTL衍生的疾病PRS模型在8种疾病的风险分层中表现出优异的性能，为将遗传资源转化为临床应用提供了一个框架。我们建立了一个在线平台“metQTL-Atlas”（https://metqtl.whu.edu.cn/home），以便于浏览和下载我们的全面研究结果。

结论：本研究提供了一个全面的资源库，描绘了不同疾病背景下代谢物的遗传结构，通过增强风险预测和治疗靶点发现，为疾病病因学提供了新见解，并推动了精准医疗的发展。

### 第二部分 AI 大师评价

本研究构建了一个涵盖40种常见疾病的血浆代谢物遗传图谱，旨在系统揭示疾病状态下代谢物的遗传调控机制。研究团队综合运用了全基因组metQTL分析、孟德尔随机化和多基因风险评分等多种前沿方法，不仅识别了大量与代谢物水平相关的遗传位点，还揭示了104个代谢物与疾病间的因果关系。这项工作的创新性在于其大规模、跨疾病的整合分析，为理解疾病的代谢基础提供了宝贵资源，并在疾病风险预测和潜在药物靶点发现方面展现出巨大的临床转化潜力。同时，配套的在线数据库“metQTL-Atlas”极大地便利了科研社群对这些数据的利用。

---

## 7. 乳酸驱动的HNRNPA1乳酸化调控PKM2剪接及膀胱癌的糖酵解重编程

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275207](https://pubmed.ncbi.nlm.nih.gov/41275207)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41275207
**DOI：** 10.1186/s13046-025-03591-5

### 第一部分 原文与翻译

**英文原标题：** Lactate-driven lactylation of HNRNPA1 orchestrates PKM2 splicing and glycolytic reprogramming in bladder cancer.

**英文摘要原文：**
BACKGROUND: Lactylation, a recently identified post-translational modification derived from lactate, has emerged as a regulator of tumor metabolism. However, its functional relevance and molecular targets in bladder cancer (BLCA) remain unclear.

METHODS: We performed immunohistochemistry on patient tissues, global lactylation proteomics using LC-MS/MS, and in vitro and in vivo functional assays. Gene editing via CRISPR/Cas9, overexpression systems, and pharmacological interventions were employed to study P300-mediated HNRNPA1-K350 lactylation in driving BLCA cell aggression. Metabolomics and glycolytic flux assays were used to assess the metabolic consequences of HNRNPA1 lactylation. Molecular characterization was validated through gene expression and splicing analyses. Small-molecule drug screening was conducted via molecular docking to identify potential inhibitors targeting HNRNPA1.

RESULTS: Protein lactylation levels were significantly elevated in BLCA tissues, correlating with poor prognosis. HNRNPA1 was identified as a central lactylation target. Glycolysis-induced lactate production promoted P300-mediated lactylation of HNRNPA1 at lysine 350, which facilitated PKM pre-mRNA splicing toward the PKM2 isoform, enhancing glycolytic flux and supporting tumor growth. Inhibition of glycolysis or LDHA knockdown reduced HNRNPA1 lactylation, suppressed PKM2 expression, and impaired BLCA cell proliferation, migration, and invasion. Metabolomic profiling linked HNRNPA1-K350 lactylation with increased aerobic glycolysis in BLCA cells. A small-molecule inhibitor, identified through molecular docking, attenuated cell proliferation by binding to HNRNPA1 and suppressing PKM2 expression.

CONCLUSIONS: This study reveals a lactate-driven mechanism coupling alternative splicing to metabolic reprogramming via HNRNPA1 lactylation, identifying HNRNPA1-K350 lactylation as a key driver of glycolysis-dependent tumor progression. A therapeutic approach targeting HNRNPA1 in BLCA is proposed.

**中文摘要译文：**
背景：乳酸化是一种新近发现的源自乳酸的翻译后修饰，已成为肿瘤代谢的调节因子。然而，其在膀胱癌（BLCA）中的功能相关性及分子靶点尚不明确。

方法：我们对患者组织进行了免疫组织化学分析，使用液相色谱-质谱联用技术（LC-MS/MS）进行了全局乳酸化蛋白质组学分析，并开展了体外与体内功能实验。我们采用CRISPR/Cas9基因编辑、过表达系统及药物干预等方法，研究了P300介导的HNRNPA1-K350位点乳酸化在驱动膀胱癌细胞侵袭性中的作用。我们使用代谢组学和糖酵解流分析来评估HNRNPA1乳酸化的代谢后果。通过基因表达和剪接分析对分子特征进行了验证。通过分子对接进行小分子药物筛选，以鉴定靶向HNRNPA1的潜在抑制剂。

结果：膀胱癌组织中的蛋白质乳酸化水平显著升高，且与不良预后相关。HNRNPA1被鉴定为一个核心的乳酸化靶点。糖酵解诱导的乳酸生成促进了P300介导的HNRNPA1赖氨酸350位点的乳酸化，这进而促进了PKM前体mRNA向PKM2亚型的剪接，从而增强糖酵解流并支持肿瘤生长。抑制糖酵解或敲降LDHA可减少HNRNPA1的乳酸化，抑制PKM2的表达，并削弱膀胱癌细胞的增殖、迁移和侵袭能力。代谢组学分析显示，HNRNPA1-K350位点的乳酸化与膀胱癌细胞有氧糖酵解的增强有关。通过分子对接筛选出的一种小分子抑制剂，能够通过与HNRNPA1结合并抑制PKM2的表达来减弱细胞增殖。

结论：本研究揭示了一种由乳酸驱动的、通过HNRNPA1乳酸化将可变剪接与代谢重编程相耦合的机制，明确了HNRNPA1-K350位点的乳酸化是糖酵解依赖性肿瘤进展的关键驱动因素。研究提出了一种在膀胱癌中靶向HNRNPA1的治疗策略。

### 第二部分 AI 大师评价

本研究创新性地揭示了乳酸作为信号分子，通过驱动HNRNPA1蛋白的乳酸化修饰，进而调控PKM2的可变剪接，最终促进膀胱癌糖酵解重编程和肿瘤进展的完整分子机制。该研究不仅深化了对肿瘤代谢（尤其是瓦博格效应）与表观遗传调控之间联系的理解，还通过筛选和验证靶向HNRNPA1的小分子抑制剂，为膀胱癌的治疗提供了极具潜力的靶点和先导化合物，展现了重要的临床转化价值。

---

## 8. 靶向SERPINB3-MAPK轴介导的铜死亡抵抗可增强抗肿瘤免疫治疗的反应。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275193](https://pubmed.ncbi.nlm.nih.gov/41275193)
**期刊：** Molecular cancer
**PMID：** 41275193
**DOI：** 10.1186/s12943-025-02529-x

### 第一部分 原文与翻译

**英文原标题：** Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy.

**英文摘要原文：**
Cuproptosis, a newly identified form of cell death, is closely linked to copper homeostasis and protein lipoylation. Using a multi-omics approach, we firstly reveal that SERPINB3 confers cuproptosis resistance in pancreatic cancer and functions as a theranostic biomarker. Mechanistically, SERPINB3 inhibits FDX1 transcription by activating the MAPK signaling pathway, thereby conferring cuproptosis resistance. We further demonstrated that SERPINB3 directly interacts with MEK1, impeding its chaperone-mediated autophagic degradation, which ultimately leads to sustained activation of the MAPK signaling pathway. Additionally, we found that SERPINB3 promotes pancreatic cancer immune evasion by upregulating PD-L1 expression on tumor cells. This phenomenon motivated the development of a triple-combination strategy consisting of MAPK inhibition, cuproptosis induction, and αPD-1 therapy for pancreatic cancer patients with high SERPINB3 expression. To this end, we further developed a metal-organic framework (MOF) loaded with both copper ions and MEK inhibitor, which significantly triggers tumor-specific cuproptosis and enhances antitumor immunity. In summary, SERPINB3 serves as a predictive biomarker to inform therapeutic strategies targeting cuproptosis, thereby establishing a novel paradigm for cancer immunotherapy that integrates metal biology, targeted therapy, and immune modulation.

**中文摘要译文：**
铜死亡（Cuproptosis）是一种新发现的细胞死亡形式，与铜稳态和蛋白质脂酰化密切相关。我们利用多组学方法，首次揭示了SERPINB3在胰腺癌中赋予细胞铜死亡抗性，并可作为一个治疗诊断生物标志物。机制上，SERPINB3通过激活MAPK信号通路抑制FDX1的转录，从而赋予铜死亡抗性。我们进一步证明，SERPINB3与MEK1直接相互作用，阻碍其分子伴侣介导的自噬降解，最终导致MAPK信号通路的持续激活。此外，我们发现SERPINB3通过上调肿瘤细胞上的PD-L1表达来促进胰腺癌的免疫逃逸。这一现象促使我们为高表达SERPINB3的胰腺癌患者开发了一种包含MAPK抑制、铜死亡诱导和αPD-1治疗的三联组合策略。为此，我们进一步开发了一种同时负载铜离子和MEK抑制剂的金属有机框架（MOF），该框架能显著触发肿瘤特异性的铜死亡并增强抗肿瘤免疫。总之，SERPINB3可作为一个预测性生物标志物，为靶向铜死亡的治疗策略提供信息，从而建立了一个整合了金属生物学、靶向治疗和免疫调节的癌症免疫治疗新范式。

### 第二部分 AI 大师评价

本研究通过多组学方法，揭示了SERPINB3在胰腺癌中通过激活MAPK信号通路赋予细胞铜死亡抗性，并上调PD-L1导致免疫逃逸的关键机制。研究的创新之处在于将新兴的铜死亡概念与肿瘤免疫逃逸直接关联，并提出了SERPINB3作为治疗诊断一体化生物标志物的潜力。更具转化价值的是，研究者设计了一种基于金属有机框架（MOF）的药物递送系统，实现了靶向抑制、铜死亡诱导与免疫治疗的三重协同，为治疗难治性胰腺癌开辟了新的道路。

---

## 9. TGF-β介导的表型变化对前列腺癌细胞失巢凋亡反应的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275067](https://pubmed.ncbi.nlm.nih.gov/41275067)
**期刊：** Oncogene
**PMID：** 41275067
**DOI：** 10.1038/s41388-025-03600-z

### 第一部分 原文与翻译

**英文原标题：** Effect of TGF-β mediated phenotypic changes on prostate cancer cell anoikis response.

**英文摘要原文：**
Epithelial mesenchymal transition (EMT) circumvents anoikis (cell death upon detachment from extracellular matrix) to promote prostate metastasis and therapy resistance. In this study, we investigated how TGF-β regulated EMT-MET (mesenchymal epithelial transition) phenotypic interconversions to enhance anoikis response in pre-clinical models of prostate cancer (PCa). We used human PCa cell line models: VCaP (androgen-sensitive, TGF-β responsive); 22RV1 (castration resistant prostate cancer); LNCaP; LNCaPTβRII (LNCaP cells overexpressing TGF-β receptor II, androgen-sensitive, TGF-β responsive); C4-2B parental and C4-2B TaxR (TGF-β unresponsive, taxane resistant). We assessed their response to TGF-β (EMT inducer) and two antitumor agents (DZ-50 and cabazitaxel (CBZ)) to understand the effect of EMT priming on anoikis vulnerability. Our findings demonstrate: (1) TGF-β induces EMT in LNCaPTβRII and apoptosis in VCaP. (2) LNCaPTβRII cells are primed by EMT to anoikis (downregulation of pSRC and cofilin). (3) Metabolic changes occur at EMT-anoikis intersection in LNCaPTβRII. (4) DZ-50 overcomes CBZ resistance in C4-2B TaxR and improves response in cells and castration-resistant organoids. These studies indicate that prostate cancer cells "programmed" to undergo phenotypic EMT become vulnerable to cell death via anoikis. Exploitation of this intersection is of potential significance in overcoming resistance to taxane chemotherapy in lethal prostate cancer. The intersection between EMT and anoikis in prostate cancer cells. TGF-β responsive prostate cancer cells respond differentially to TGF-β by undergoing epithelial mesenchymal transition EMT (LNCaPTβRII and VCaP) or apoptosis (VCaP). TGF-β induced EMT further sensitizes LNCaPTβRII to DZ-50 induced anoikis. DZ-50-associated anoikis cell death in prostate cancer cells is associated with (i) phenotypic reprogramming (EMT to mesenchymal epithelial transition (MET)) (ii) inactivation of SRC (decreased pSRC) (iii) decreased cofilin expression in LNCaPTβRII and VCaP cells.

**中文摘要译文：**
上皮间质转化（EMT）通过规避失巢凋亡（细胞脱离细胞外基质后发生的死亡）来促进前列腺癌的转移和治疗抵抗。在本研究中，我们探讨了在前列腺癌（PCa）的临床前模型中，TGF-β如何调控EMT-MET（间质上皮转化）的表型互变以增强失巢凋亡反应。我们使用了多种人前列腺癌细胞系模型：VCaP（雄激素敏感，TGF-β响应型）；22RV1（去势抵抗性前列腺癌）；LNCaP；LNCaPTβRII（过表达TGF-β II型受体的LNCaP细胞，雄激素敏感，TGF-β响应型）；C4-2B亲本细胞及C4-2B TaxR（TGF-β无响应，紫杉烷类药物抵抗型）。我们评估了这些细胞对TGF-β（EMT诱导剂）和两种抗肿瘤药物（DZ-50和卡巴他赛(CBZ)）的反应，以理解EMT启动对失巢凋亡易感性的影响。我们的研究结果表明：（1）TGF-β在LNCaPTβRII细胞中诱导EMT，在VCaP细胞中诱导凋亡。（2）EMT启动使LNCaPTβRII细胞对失巢凋亡变得敏感（表现为pSRC和cofilin的下调）。（3）在LNCaPTβRII细胞中，EMT与失巢凋亡的交汇点上发生了代谢变化。（4）DZ-50能够克服C4-2B TaxR细胞对CBZ的耐药性，并改善细胞和去势抵抗性类器官的治疗反应。这些研究表明，被“编程”进行表型EMT的前列腺癌细胞，会变得易于通过失巢凋亡途径死亡。利用这一交汇点对于克服致死性前列腺癌的紫杉烷类化疗耐药具有潜在的重要意义。前列腺癌细胞中EMT与失巢凋亡的交汇作用。TGF-β响应型前列腺癌细胞对TGF-β产生差异性反应，或发生上皮间质转化（EMT）（LNCaPTβRII和VCaP），或发生凋亡（VCaP）。TGF-β诱导的EMT进一步使LNCaPTβRII细胞对DZ-50诱导的失巢凋亡敏感。在前列腺癌细胞中，与DZ-50相关的失巢凋亡性细胞死亡与以下因素相关：（i）表型重编程（从EMT到间质上皮转化（MET）），（ii）SRC的失活（pSRC减少），以及（iii）LNCaPTβRII和VCaP细胞中cofilin表达的降低。

### 第二部分 AI 大师评价

本研究旨在探究TGF-β介导的上皮间质转化（EMT）如何影响前列腺癌细胞的失巢凋亡，并试图利用此机制克服治疗耐药。研究者通过多种前列腺癌细胞系和类器官模型发现，EMT过程竟能“启动”细胞，使其对后续药物（如DZ-50）诱导的失巢凋亡更加敏感，这一发现揭示了EMT在促进癌细胞可塑性的同时，也可能成为其弱点。该研究的创新之处在于将EMT与治疗脆弱性联系起来，为克服晚期前列腺癌的紫杉烷类药物耐药性提供了一个全新的潜在策略，具有重要的临床转化价值。

---

## 10. SNAP23缺陷触发Trim21线粒体易位以抑制TFAM介导的氧化代谢并驱动结直肠癌的化疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274938](https://pubmed.ncbi.nlm.nih.gov/41274938)
**期刊：** Cell death & disease
**PMID：** 41274938
**DOI：** 10.1038/s41419-025-08252-1

### 第一部分 原文与翻译

**英文原标题：** SNAP23 deficiency triggers Trim21 mitochondrial translocation to suppress TFAM-mediated oxidative metabolism and drive chemoresistance in colorectal cancer.

**英文摘要原文：**
Chemoresistance is a major cause of poor prognosis in colorectal cancer (CRC), and its molecular mechanisms urgently need elucidation. The cell membrane protein SNAP23, known for its role in vesicle secretion, also promotes CRC cell growth. However, its role in tumor chemotherapy remains unclear. This study reveals a novel function of SNAP23, independent of vesicle transport, mediating crosstalk between the cell membrane and mitochondria to influence the chemotherapeutic response to oxaliplatin (OXA). Mechanistically, SNAP23 arrests Trim21, causing its accumulation near the cell membrane and away from mitochondria. This reduces the ubiquitination and degradation of the mitochondrial transcription factor A (TFAM), enhancing mitochondrial oxidative metabolism and increasing oxidative phosphorylation (OXPHOS) and reactive oxygen species (ROS) production, ultimately heightening the sensitivity of cancer cells to OXA. The unique regulatory function of SNAP23 in the chemotherapeutic response of colorectal cancer may provide a potential target for chemotherapy sensitization.

**中文摘要译文：**
化疗耐药是结直肠癌（CRC）预后不良的主要原因，其分子机制亟待阐明。细胞膜蛋白SNAP23以其在囊泡分泌中的作用而闻名，同时也能促进CRC细胞的生长。然而，其在肿瘤化疗中的作用尚不明确。本研究揭示了SNAP23一个独立于囊泡运输的新功能，即介导细胞膜与线粒体之间的串扰，以影响对奥沙利铂（OXA）的化疗反应。从机制上讲，SNAP23会阻滞Trim21，导致其在细胞膜附近积聚而远离线粒体。这会减少线粒体转录因子A（TFAM）的泛素化和降解，从而增强线粒体氧化代谢，增加氧化磷酸化（OXPHOS）和活性氧（ROS）的产生，最终提高癌细胞对OXA的敏感性。SNAP23在结直肠癌化疗反应中的独特调节功能可能为化疗增敏提供一个潜在靶点。

### 第二部分 AI 大师评价

本研究旨在探讨细胞膜蛋白SNAP23在结直肠癌奥沙利铂化疗耐药中的作用及其分子机制。研究关键发现，SNAP23通过在细胞膜区域“扣押”Trim21蛋白，阻止其进入线粒体，进而稳定了线粒体转录因子TFAM，增强了线粒体的氧化代谢，最终提升了癌细胞对化疗的敏感性。该研究的创新之处在于揭示了一条独立于囊泡运输功能的“细胞膜-线粒体”通讯新途径，为理解和克服结直肠癌化疗耐药提供了新的分子靶点和理论依据，具有重要的潜在临床转化价值。

---

## 11. 解析组蛋白修饰在转录抑制中的特异性作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274922](https://pubmed.ncbi.nlm.nih.gov/41274922)
**期刊：** Nature communications
**PMID：** 41274922
**DOI：** 10.1038/s41467-025-66426-z

### 第一部分 原文与翻译

**英文原标题：** Addressing the specific roles of histone modifications in transcriptional repression.

**英文摘要原文：**
Our understanding of epigenetic processes is based on the hypothesis that individual posttranslational modifications of DNA and histones, or combinations thereof, function to direct unique downstream effects on transcription. Still, histone modifications are broadly categorized as repressive or activating, raising the question of potential functional redundancy. Here, we present an approach for addressing this question by substituting the genome-wide H3K27me3 pattern with other histone modifications. By taking advantage of the modular organization of PRC2, we direct de novo recruitment of H3K9me3 and H3K36me3 to PRC2 target genes in H3K27me3 null mouse embryonic stem cells (mESCs). We show that despite accurate genome-wide re-establishment of H3K36me3 at PRC2 target genes, which leads to significant reduction in H3K4me3 levels, the remaining H3K4me3 prevents H3K36me3 from recruiting sufficient DNA methylation to substitute for H3K27me3-mediated repression. In contrast, we demonstrate that H3K9me3 is more efficient in repressing H3K27me3 regulated genes, however this repression is also contingent on H3K4me3 status. Taken together, these results highlight the unique repressive functions of H3K27me3 and suggest that the functional effects of individual posttranslational modifications are highly dependent on the interplay with the existing chromatin environment.

**中文摘要译文：**
我们对表观遗传过程的理解基于这样一个假说：DNA和组蛋白的单个翻译后修饰或其组合，能够指导对转录产生独特的下游效应。然而，组蛋白修饰通常被宽泛地分为抑制性或激活性，这引发了其功能上是否存在冗余的问题。在本研究中，我们提出了一种解决该问题的方法，即用其他组蛋白修饰替换全基因组范围内的H3K27me3模式。利用PRC2的模块化组织结构，我们在H3K27me3缺失的小鼠胚胎干细胞（mESCs）中，将H3K9me3和H3K36me3从头招募至PRC2的靶基因上。我们发现，尽管在PRC2靶基因上精确地全基因组重建了H3K36me3，并导致H3K4me3水平显著下降，但残留的H3K4me3阻止了H3K36me3招募足够的DNA甲基化来替代H3K27me3介导的抑制作用。相比之下，我们证明H3K9me3在抑制H3K27me3调控的基因方面效率更高，然而这种抑制作用同样依赖于H3K4me3的状态。综上所述，这些结果凸显了H3K27me3独特的抑制功能，并表明单个翻译后修饰的功能效应高度依赖于与现有染色质环境的相互作用。

### 第二部分 AI 大师评价

该研究旨在探究不同抑制性组蛋白修饰（特别是H3K27me3）在转录调控中是否具有不可替代的特异性功能。研究者巧妙地利用基因工程技术，在小鼠胚胎干细胞中将H3K27me3“替换”为H3K9me3或H3K36me3，并直接比较其功能。核心发现表明，H3K9me3和H3K36me3均无法完全替代H3K27me3的抑制作用，且其效果受到现有染色质环境（如H3K4me3水平）的显著影响。这项工作通过创新的“修饰互换”方法，有力地证明了H3K27me3功能的独特性，深化了我们对表观遗传调控“密码”复杂性和情境依赖性的认识，对理解发育和疾病中的表观遗传机制具有重要价值。

---

## 12. 分化的前额叶皮层环路在不同代谢或情绪状态下调控线索提示的觅食行为。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274918](https://pubmed.ncbi.nlm.nih.gov/41274918)
**期刊：** Nature communications
**PMID：** 41274918
**DOI：** 10.1038/s41467-025-65347-1

### 第一部分 原文与翻译

**英文原标题：** Divergent prefrontal cortex circuits regulate cued food seeking under distinct metabolic or emotional states.

**英文摘要原文：**
Flexibly adjusting food-seeking behaviour in response to food-associated cues and internal states is crucial for animals' survival. However, the neural mechanisms that modulate cued food-seeking behaviour during varying metabolic (i.e., hungry vs. satiated) and emotional (i.e., safe vs. threatened) states remain elusive. Here, we show that the encoding of metabolic or threat states in projection-defined neurons in the prelimbic cortex (PL) mediates cued food-seeking responses in rats. Using microendoscopic imaging, we demonstrate that neural population dynamics in PL consistently represent food cues, task-relevant behaviours, and internal state changes by recruiting distinct subsets of cue-responsive neurons at each state. Single-unit recording and loss-of-function experiments reveal that activity in divergent PL projections to the anterior paraventricular nucleus of the thalamus (aPVT) or the nucleus accumbens (NAc) promotes either hedonic feeding during satiation or food-seeking suppression during threat, respectively. Together, our findings uncover a mechanism by which divergent PL circuits regulate cued food-seeking under distinct metabolic or emotional states.

**中文摘要译文：**
根据食物相关线索和内部状态灵活调整觅食行为对动物的生存至关重要。然而，在变化的代谢（即饥饿与饱腹）和情绪（即安全与受威胁）状态下，调节线索提示的觅食行为的神经机制仍不清楚。在此，我们揭示了前边缘皮层（PL）中特定投射神经元对代谢或威胁状态的编码介导了大鼠在线索提示下的觅食反应。通过使用微型内窥镜成像技术，我们证明了PL区的神经元群体动态通过在每种状态下招募不同的线索反应性神经元子集，来持续地表征食物线索、任务相关行为以及内部状态的变化。单细胞记录和功能丧失实验表明，PL区到丘脑前室旁核（aPVT）或伏隔核（NAc）的不同投射活动分别促进了饱腹状态下的享乐性进食或威胁状态下的觅食抑制。总之，我们的研究结果揭示了一种机制，即分化的PL环路在不同的代谢或情绪状态下调控线索提示的觅食行为。

### 第二部分 AI 大师评价

本研究旨在揭示前额叶皮层（PL）如何根据饥饿或恐惧等不同内部状态来调控觅食行为。研究人员综合运用了微型内窥镜成像和功能操控等先进技术，精准地识别出两条从PL区发出、分别投射到丘脑（aPVT）和伏隔核（NAc）的关键神经环路。研究发现，PL-aPVT环路在饱腹时驱动享乐性进食，而PL-NAc环路则在面临威胁时抑制觅食。这项发现不仅精细地阐明了大脑根据内在需求灵活控制行为的神经机制，也为理解和干预饮食失调、成瘾等相关疾病提供了新的靶点和思路。

---

## 13. 交流电预处理增强高熵合金纳米酶的多酶活性，通过代谢调控实现有效的肿瘤免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274897](https://pubmed.ncbi.nlm.nih.gov/41274897)
**期刊：** Nature communications
**PMID：** 41274897
**DOI：** 10.1038/s41467-025-66657-0

### 第一部分 原文与翻译

**英文原标题：** Alternating current pre-treatment enhances multi-enzymatic activity of high-entropy alloy nanozymes that regulate metabolism for effective tumor immunotherapy.

**英文摘要原文：**
Nanozymes capable of inducing metabolic reprogramming and activating the immune response without external stimuli in vivo are highly pursued for malignant tumor therapy. In this paper, a PtIrFeMoZn high-entropy alloy (HEA) nanozyme is designed and synthesized via a simple one-step hydrothermal method. The HEA nanozymes not only trigger apoptosis and ferroptosis via cascade biocatalysis, thereby enhancing immunogenicity, but also enhance the immune effect by targeting the glycolytic pathway. It is worth mentioning that a simple pre-treatment of nanozymes by alternating current (AC) yielded much better therapeutic and immuno-effect. The 'AC-treated' nanozymes exhibit an excellent synergy of peroxidase-like (POD-like), myeloperoxidase-like (MPO-like), and glutathione peroxidase-like (GPx-like) activities, generating a sufficient reactive oxygen species (ROS) storm. Additionally, two immune pathways (ICD and the cGAS-STING) are activated simultaneously. Furthermore, the production of HClO and the depletion of NADH can regulate metabolism, further disrupting the equilibrium of the glycolysis process. This not only increases the cell death but also enhances the immune response in female tumor-bearing mice. This study proposes a multi-pronged therapeutic strategy that can significantly activate anti-tumor immunotherapeutic effects through ROS storm, GSH/NADH oxidation, and lactate/ATP depletion, triggering apoptosis/ferroptosis/immunotherapy. These findings hold significant promise for inspiring the development of HEA nanozymes for tumor immunotherapy.

**中文摘要译文：**
能够在体内无外部刺激下诱导代谢重编程并激活免疫应答的纳米酶，是恶性肿瘤治疗领域的研究热点。本文通过简单的一步水热法设计并合成了一种PtIrFeMoZn高熵合金（HEA）纳米酶。该高熵合金纳米酶不仅通过级联生物催化作用触发细胞凋亡和铁死亡，从而增强免疫原性，还能通过靶向糖酵解途径增强免疫效应。值得一提的是，通过简单的交流电（AC）预处理，该纳米酶展现出更优的治疗和免疫效果。“经交流电处理”的纳米酶表现出优异的类过氧化物酶（POD-like）、类髓过氧化物酶（MPO-like）和类谷胱甘肽过氧化物酶（GPx-like）协同活性，能产生足量的活性氧（ROS）风暴。此外，两条免疫通路（ICD和cGAS-STING）被同时激活。再者，次氯酸（HClO）的产生和烟酰胺腺嘌呤二核苷酸（NADH）的消耗能够调节代谢，进一步打破糖酵解过程的平衡。这不仅增加了细胞死亡，也增强了雌性荷瘤小鼠的免疫应答。本研究提出了一种多管齐下的治疗策略，通过活性氧风暴、谷胱甘肽/烟酰胺腺嘌呤二核苷酸（GSH/NADH）氧化以及乳酸/三磷酸腺苷（ATP）耗竭，触发细胞凋亡/铁死亡/免疫治疗，从而显著激活抗肿瘤免疫治疗效果。这些发现为启发用于肿瘤免疫治疗的高熵合金纳米酶的开发带来了重要前景。

### 第二部分 AI 大师评价

本研究旨在开发一种新型高熵合金纳米酶，用于无需外界刺激的肿瘤免疫治疗。研究团队通过创新的交流电（AC）预处理方法，显著增强了PtIrFeMoZn纳米酶的多重酶学活性。核心发现是，经AC处理的纳米酶能引发活性氧风暴并调控肿瘤细胞的糖酵解代谢，从而协同激活细胞凋亡、铁死亡及cGAS-STING等多条抗肿瘤通路。这项工作的创新之处在于提出了一种简单有效的物理方法来“激活”纳米酶，其多管齐下的治疗策略为开发高效、低副作用的肿瘤免疫疗法提供了极具价值的新思路。

---

## 14. BCL-xL复合物的尾锚对BH3-沟槽相互作用的变构调节限制了BH3模拟物的拮抗作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274891](https://pubmed.ncbi.nlm.nih.gov/41274891)
**期刊：** Nature communications
**PMID：** 41274891
**DOI：** 10.1038/s41467-025-65509-1

### 第一部分 原文与翻译

**英文原标题：** Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism.

**英文摘要原文：**
BCL-xL promotes cell survival by binding BH3-only initiators through its hydrophobic groove. Combining resonance energy transfer assays and molecular dynamics simulations, we unravel that membrane anchoring of BCL-xL via its tail anchor selectively advantages binding to membrane-anchored PUMA initiator over BH3 mimetic ligands of the groove. This is due to the combined allosteric effect on BH3-in-groove binding of BCL-xL and PUMA tail anchors. Moreover, doubly anchored PUMA / BCL-xL complexes recruit endogenous BAX, which favors their antagonism by BH3 mimetics. BAX's tail anchor alone is sufficient to enhance BH3 mimetics-induced death in cells expressing PUMA / BCL-xL. Our work supports a model in which the survival function of BCL-xL is regulated by a complex interplay between its tail anchor and those of its interacting partners. This enables both resistance to pharmacological inhibitors and modulation by BAX, which functions as a crucial feedback disruptor of the BCL-xL network.

**中文摘要译文：**
BCL-xL通过其疏水沟槽结合仅含BH3结构域的凋亡起始蛋白来促进细胞存活。我们结合共振能量转移实验和分子动力学模拟，揭示了BCL-xL通过其尾锚锚定于膜上时，相比于沟槽的BH3模拟物配体，其与同样锚定于膜上的PUMA凋亡起始蛋白的结合更具选择性优势。这是由于BCL-xL和PUMA的尾锚对BH3-沟槽结合产生的联合变构效应所致。此外，双锚定的PUMA / BCL-xL复合物会招募内源性的BAX，这有利于BH3模拟物对其发挥拮抗作用。在表达PUMA / BCL-xL的细胞中，仅BAX的尾锚就足以增强BH3模拟物诱导的细胞死亡。我们的工作支持一个模型，即BCL-xL的促存活功能受到其尾锚与其相互作用伙伴尾锚之间复杂相互作用的调控。这种调控机制既能导致对药物抑制剂的耐药，也能被BAX所调节，而BAX在此过程中扮演了BCL-xL网络关键反馈破坏者的角色。

### 第二部分 AI 大师评价

本研究通过结合能量共振转移实验与分子动力学模拟，旨在阐明BCL-xL蛋白的膜锚定机制如何变构调控其与凋亡蛋白及BH3模拟物的相互作用。核心发现揭示了BCL-xL及其互作蛋白（如PUMA和BAX）的尾锚在膜上的动态互作，是决定其亲和力及对BH3模拟物敏感性的关键。这项工作不仅为理解BH3模拟物耐药性提供了新的分子机制，也指出了BAX作为BCL-xL网络关键反馈破坏者的角色，为开发更有效的抗癌策略提供了重要的理论依据和潜在靶点。

---

## 15. 基于益生菌的口服疫苗粘膜递送系统：实现基因编码的双抗原阵列

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274888](https://pubmed.ncbi.nlm.nih.gov/41274888)
**期刊：** Nature communications
**PMID：** 41274888
**DOI：** 10.1038/s41467-025-66622-x

### 第一部分 原文与翻译

**英文原标题：** Probiotic-based oral vaccine mucosal delivery system enabling genetically encoded dual-antigen arrays.

**英文摘要原文：**
Oral vaccines provide a non-invasive approach for cancer immunotherapy but face challenges in gastrointestinal stability, antigen presentation, and mucosal delivery. Here, we present an engineered probiotic-based oral vaccine system, Bac, featuring genetically encoded dual-antigen ferritin arrays and inducible bacterial lysis. Upon oral administration and arabinose induction, the probiotic strain lyses in situ, releasing OVA/TRP2-decorated ferritin nanoparticles that efficiently traverse the intestinal barrier via M-cell targeting and activate mucosal dendritic cells. This platform robustly stimulates CD8 and CD4 T-cell responses, enhances B-cell and macrophage activation, reduces regulatory T cells, and provides therapeutic efficacy against melanoma in both lung metastasis and subcutaneous tumor models. It also establishes durable immunological memory without disrupting systemic or mucosal homeostasis. This work offers a programmable bacterial chassis for precise antigen array presentation and controlled delivery, representing a promising strategy for next-generation, needle-free cancer vaccines.

**中文摘要译文：**
口服疫苗为癌症免疫治疗提供了一种非侵入性方法，但面临胃肠道稳定性、抗原呈递和粘膜递送等挑战。在此，我们展示了一种经过工程改造的、基于益生菌的口服疫苗系统（Bac），其特点是具有基因编码的双抗原铁蛋白阵列和可诱导的细菌裂解功能。经口服给药和阿拉伯糖诱导后，该益生菌菌株会原位裂解，释放出经OVA/TRP2修饰的铁蛋白纳米颗粒，这些纳米颗粒能通过靶向M细胞高效穿过肠道屏障并激活粘膜树突状细胞。该平台能有效刺激CD8和CD4 T细胞应答，增强B细胞和巨噬细胞的活化，减少调节性T细胞，并在肺转移和皮下肿瘤模型中均表现出对黑色素瘤的治疗效果。它还能建立持久的免疫记忆，且不破坏全身或粘膜的稳态。这项工作提供了一种可编程的细菌底盘，用于精确的抗原阵列呈递和可控递送，代表了下一代无针癌症疫苗的一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在开发一种新型的非侵入性口服癌症疫苗。研究团队设计了一种基于工程益生菌的递送系统，该系统能被诱导在肠道内裂解，并释放出携带双肿瘤抗原的纳米颗粒，从而精准激活粘膜免疫。关键发现表明，该口服疫苗在黑色素瘤模型中展现出显著的治疗效果，并能建立持久的免疫记忆，且不破坏机体稳态。这项工作巧妙地结合了合成生物学与纳米技术，为开发安全、有效、便捷的“无针”癌症疫苗提供了一种极具前景的新策略。

---

## 16. 扩大异基因干细胞移植对急性髓系白血病生存率的影响：一项基于人群的研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274886](https://pubmed.ncbi.nlm.nih.gov/41274886)
**期刊：** Blood cancer journal
**PMID：** 41274886
**DOI：** 10.1038/s41408-025-01416-4

### 第一部分 原文与翻译

**英文原标题：** Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究是一项基于人群的大样本分析，旨在评估异基因干细胞移植应用的扩展对急性髓系白血病（AML）患者总体生存率的实际影响。通过分析大规模真实世界数据，该研究可能揭示了移植策略的变化是否改善了AML患者的预后，并为优化移植适应症和资源配置提供了重要证据。尽管缺乏摘要限制了对其具体发现的深入了解，但此类研究对于验证临床试验结果在常规医疗实践中的有效性、指导宏观卫生政策具有关键价值。

---

## 17. 脑/肝葡萄糖摄取比值与非霍奇金淋巴瘤CAR-T治疗预后的关系

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274867](https://pubmed.ncbi.nlm.nih.gov/41274867)
**期刊：** Blood cancer journal
**PMID：** 41274867
**DOI：** 10.1038/s41408-025-01425-3

### 第一部分 原文与翻译

**英文原标题：** The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探索一个影像学生物标志物——脑/肝葡萄糖摄取比值，在接受CAR-T细胞治疗的非霍奇金淋巴瘤患者中的预后预测价值。该研究可能通过分析患者治疗前的PET-CT影像数据，将其与治疗反应或生存率等临床结局进行关联分析。尽管缺乏摘要信息，但该标题揭示了一个潜在的创新点：利用一个相对容易获取且标准化的影像指标来对接受昂贵且高风险CAR-T治疗的患者进行风险分层，这可能为临床决策和个体化治疗提供新的无创性预测工具，具有重要的临床转化潜力。

---

## 18. 不可切除肝细胞癌的治疗：来自CheckMate 9DW研究的见解——作者的回复

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274758](https://pubmed.ncbi.nlm.nih.gov/41274758)
**期刊：** Lancet (London, England)
**PMID：** 41274758
**DOI：** 10.1016/S0140-6736(25)02049-5

### 第一部分 原文与翻译

**英文原标题：** Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW - Authors' reply.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献是针对CheckMate 9DW研究的“作者回复”，并非原创性研究论文。其核心目的在于回应学术界对原研究的疑问或评论，以澄清研究细节、数据解读或结论。由于缺乏摘要信息，无法评估其具体方法和发现，但这类文献对于促进学术交流、确保研究透明度和加深对大型临床试验（如CheckMate 9DW）的理解具有重要价值。

---

## 19. 不可切除肝细胞癌的治疗：来自CheckMate 9DW研究的启示

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274757](https://pubmed.ncbi.nlm.nih.gov/41274757)
**期刊：** Lancet (London, England)
**PMID：** 41274757
**DOI：** 10.1016/S0140-6736(25)01799-4

### 第一部分 原文与翻译

**英文原标题：** Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题揭示了其内容核心是基于CheckMate 9DW研究结果，对不可切除肝细胞癌（uHCC）的治疗策略进行深入解读。尽管缺乏摘要，但从标题可推断，本文旨在评述CheckMate 9DW这一重要临床试验的关键发现，可能涉及新型免疫联合疗法在uHCC一线治疗中的应用。此类述评对于临床医生理解前沿临床试验数据、权衡不同治疗方案的利弊以及指导个体化治疗决策具有重要的参考价值。

---

## 20. 不可切除肝细胞癌的治疗：来自CheckMate 9DW研究的启示

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274755](https://pubmed.ncbi.nlm.nih.gov/41274755)
**期刊：** Lancet (London, England)
**PMID：** 41274755
**DOI：** 10.1016/S0140-6736(25)01800-8

### 第一部分 原文与翻译

**英文原标题：** Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这是一篇针对CheckMate 9DW研究的评论或解读性文章，该研究是关于不可切除肝细胞癌（HCC）治疗领域的一项重要临床试验。文章的核心目的可能是深入分析并提炼CheckMate 9DW研究的关键发现，特别是评估某种新疗法（如免疫联合疗法）相较于标准疗法的疗效与安全性。尽管缺乏摘要，但从标题推断，本文旨在探讨该研究结果对晚期HCC一线治疗策略的临床启示和潜在影响，可能为临床医生提供新的治疗见解。

---

## 21. 欧盟在公共卫生紧急状态下对临床试验的集中伦理审查

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274751](https://pubmed.ncbi.nlm.nih.gov/41274751)
**期刊：** Lancet (London, England)
**PMID：** 41274751
**DOI：** 10.1016/S0140-6736(25)02054-9

### 第一部分 原文与翻译

**英文原标题：** Centralised ethics review of clinical trials in a public health emergency in the EU.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文献标题揭示了其核心议题：探讨在公共卫生紧急事件背景下，欧盟如何对临床试验进行集中化的伦理审查。尽管缺乏摘要信息，但从标题可以推断，该文可能是一篇政策分析或评论性文章，旨在审视现有审查流程的效率与挑战。这一主题具有重要的现实意义，尤其在全球性大流行病之后，建立高效、统一的伦理审查机制对于加速关键研究至关重要，可能为优化应急科研响应机制提供宝贵的政策视角。

---

## 22. 安伯尼塔单抗联合化疗治疗既往含曲妥珠单抗方案治疗失败的HER2阳性胃癌或胃食管交界处癌患者：一项多中心、II期研究（KC-WISE 01）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41273757](https://pubmed.ncbi.nlm.nih.gov/41273757)
**期刊：** Cancer communications (London, England)
**PMID：** 41273757
**DOI：** 10.1002/cac2.70080

### 第一部分 原文与翻译

**英文原标题：** Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01).

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究是一项多中心的II期临床试验，旨在评估新型抗体药物安伯尼塔单抗联合化疗，在既往接受过曲妥珠单抗治疗失败的HER2阳性胃癌或胃食管交界处癌患者中的疗效与安全性。这项研究聚焦于一个存在显著未满足临床需求的患者群体，探索了新的治疗策略，具有重要的临床意义。由于摘要缺失，无法得知其具体的试验结果和关键发现，但该研究的设计为评估安伯尼塔单抗在后线治疗中的潜在价值提供了关键证据。

---

速递结束，祝您工作愉快！